Literature DB >> 19933789

Prevention of severe cutaneous adverse drug reactions: the emerging value of pharmacogenetic screening.

Suran L Fernando1, Andrew J Broadfoot.   

Abstract

Mesh：

Substances：

Year:  2009        PMID： 19933789      PMCID： PMC2842859          DOI： 10.1503/cmaj.090401

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  22 in total

1.  Medical genetics: a marker for Stevens-Johnson syndrome.

Authors:  Wen-Hung Chung; Shuen-Iu Hung; Hong-Shang Hong; Mo-Song Hsih; Li-Cheng Yang; Hsin-Chun Ho; Jer-Yuarn Wu; Yuan-Tsong Chen
Journal:  Nature       Date:  2004-04-01       Impact factor: 49.962

2.  Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study.

Authors:  A Rauch; D Nolan; A Martin; E McKinnon; C Almeida; Simon Mallal
Journal:  Clin Infect Dis       Date:  2006-05-26       Impact factor: 9.079

Review 3.  Pharmacogenetics and geographical ancestry: implications for drug development and global health.

Authors:  Abdallah S Daar; Peter A Singer
Journal:  Nat Rev Genet       Date:  2005-03       Impact factor: 53.242

4.  A marker for Stevens-Johnson syndrome ...: ethnicity matters.

Authors:  C Lonjou; L Thomas; N Borot; N Ledger; C de Toma; H LeLouet; E Graf; M Schumacher; A Hovnanian; M Mockenhaupt; J-C Roujeau
Journal:  Pharmacogenomics J       Date:  2006-01-17       Impact factor: 3.550

Review 5.  Pathogenesis and recent therapeutic trends in Stevens-Johnson syndrome and toxic epidermal necrolysis.

Authors:  Barzin Khalili; Sami L Bahna
Journal:  Ann Allergy Asthma Immunol       Date:  2006-09       Impact factor: 6.347

6.  Relation between adverse events associated with allopurinol and renal function in patients with gout.

Authors:  J Vázquez-Mellado; E M Morales; C Pacheco-Tena; R Burgos-Vargas
Journal:  Ann Rheum Dis       Date:  2001-10       Impact factor: 19.103

7.  Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity.

Authors:  Sinforiano J Posadas; Antonia Padial; Maria J Torres; Cristobalina Mayorga; Laura Leyva; Elena Sanchez; Javier Alvarez; Antonino Romano; Carlos Juarez; Miguel Blanca
Journal:  J Allergy Clin Immunol       Date:  2002-01       Impact factor: 10.793

8.  Soluble FAS ligand: a discriminating feature between drug-induced skin eruptions and viral exanthemas.

Authors:  Karoline Stur; Franz M Karlhofer; Georg Stingl
Journal:  J Invest Dermatol       Date:  2006-11-30       Impact factor: 8.551

9.  HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol.

Authors:  Shuen-Iu Hung; Wen-Hung Chung; Lieh-Bang Liou; Chen-Chung Chu; Marie Lin; Hsien-Ping Huang; Yen-Ling Lin; Joung-Liang Lan; Li-Cheng Yang; Hong-Shang Hong; Ming-Jing Chen; Ping-Chin Lai; Mai-Szu Wu; Chia-Yu Chu; Kuo-Hsien Wang; Chien-Hsiun Chen; Cathy S J Fann; Jer-Yuarn Wu; Yuan-Tsong Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-02       Impact factor: 11.205

10.  Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions.

Authors:  Shuen-Iu Hung; Wen-Hung Chung; Shiou-Hwa Jee; Wen-Chieh Chen; Yun-Ting Chang; Woan-Ruoh Lee; Shu-Ling Hu; Meng-Tse Wu; Gwo-Shing Chen; Tak-Wah Wong; Pa-Fan Hsiao; Wei-Hsuan Chen; Han-Yu Shih; Wu-Hsiang Fang; Chun-Yu Wei; Yi-Hui Lou; Yau-Li Huang; Juei-Jueng Lin; Yuan-Tsong Chen
Journal:  Pharmacogenet Genomics       Date:  2006-04       Impact factor: 2.089
View more
  11 in total

1.  Predictive genotype.

Authors:  Shinya Ito; Bruce C Carleton
Journal:  CMAJ       Date:  2010-05-18       Impact factor: 8.262

2.  Pharmacogenetic screening.

Authors:  Abdelbaset A Elzagallaai
Journal:  CMAJ       Date:  2010-07-13       Impact factor: 8.262

Review 3.  Epidemiology and risk factors for drug allergy.

Authors:  Bernard Y-H Thong; Teck-Choon Tan
Journal:  Br J Clin Pharmacol       Date:  2011-05       Impact factor: 4.335

4.  Pharmacogenetic Gene-Drug Associations in Pediatric Burn and Surgery Patients.

Authors:  Kristin N Grimsrud; Ryan R Davis; Clifford G Tepper; Tina L Palmieri
Journal:  J Burn Care Res       Date:  2022-09-01       Impact factor: 1.819

5.  PharmGKB summary: very important pharmacogene information for human leukocyte antigen B.

Authors:  Julia M Barbarino; Deanna L Kroetz; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2015-04       Impact factor: 2.089

6.  Toxic epidermal necrolysis - management issues and treatment options.

Authors:  Alan D Widgerow
Journal:  Int J Burns Trauma       Date:  2011-09-03

7.  HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in Vietnamese.

Authors:  Dinh Van Nguyen; Hieu Chi Chu; Doan Van Nguyen; Minh Hong Phan; Timothy Craig; Karl Baumgart; Sheryl van Nunen
Journal:  Asia Pac Allergy       Date:  2015-04-29

8.  A high-resolution HLA imputation system for the Taiwanese population: a study of the Taiwan Biobank.

Authors:  Yu-Han Huang; Seik-Soon Khor; Xiuwen Zheng; Hsuan-Yu Chen; Ya-Hsuan Chang; Hou-Wei Chu; Pei-Ei Wu; Yu-Ju Lin; Shu-Fen Liao; Chen-Yang Shen; Katsushi Tokunaga; Mei-Hsuan Lee
Journal:  Pharmacogenomics J       Date:  2020-02-11       Impact factor: 3.550

9.  A world allergy organization international survey on diagnostic procedures and therapies in drug allergy/hypersensitivity.

Authors:  Bernard Yu-Hor Thong; Rita Mirakian; Mariana Castells; Werner Pichler; Antonino Romano; Patrizia Bonadonna; Deleanu Diana; Marek Kowalski; Anahi Yanez; Ramon Lleonart; Mario Sanchez-Borges; Pascal Demoly
Journal:  World Allergy Organ J       Date:  2011-12-14       Impact factor: 4.084

10.  Reactivation of cytomegalovirus in a patient with stevens-johnson syndrome-toxic epidermal necrolysis.

Authors:  Mohamed Rida Tagajdid; Taoufik Doblali; Hicham Elannaz; Salaheddine Hammi; Bouchra Belfequih; Saâd Mrani
Journal:  Iran J Med Sci       Date:  2013-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.